Spero Therapeutics (SPRO) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Spero Therapeutics had a P/E ratio of 15.31, return on equity of 16.3% (up from -89.6%), debt-to-equity of 0.05 (down from 0.09) and a current ratio of 7.59 (up from 2.19). A current ratio of 7.59 means current assets exceed current liabilities.

Spero Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	15.31	-	3.42	-	-	-
Forward P/E	4.88	-	-	-	-	-
P/S Ratio	1.97	1.17	0.75	1.67	28.35	56.50
P/B Ratio	2.22	1.22	0.73	1.18	5.86	3.99
Price/Tangible Book	2.22	1.22	0.73	1.18	5.86	3.99
Enterprise Value Ratios
EV/Revenue	1.29	-	-	0.86	21.98	43.73
EV/EBITDA	12.01	-	-	-	-	-
EV/EBIT	12.01	-	-	-	-	-
Profitability & Returns
Return on Equity (ROE)	16.31%	-89.62%	24.95%	-56.53%	-81.47%	-75.77%
Return on Assets (ROA)	4.99%	-30.93%	10.90%	-12.91%	-33.88%	-38.10%
Return on Invested Capital (ROIC)	72.44%	-431.00%	502.14%	-	-1658.58%	-1432.43%
Return on Capital Employed (ROCE)	11.90%	-117.90%	18.40%	-29.60%	-57.70%	-56.90%
Leverage & Solvency Ratios
Debt/Equity	0.05	0.09	0.05	0.09	0.63	0.06
Debt/EBITDA	0.34	-	0.19	-	-	-
Liquidity Ratios
Current Ratio	7.59	2.19	3.53	5.25	8.46	9.70
Quick Ratio	7.40	2.15	3.42	5.09	7.98	9.28
Efficiency Ratios
Asset Turnover	0.74	0.33	0.68	0.36	0.11	0.07
Yield & Distribution Ratios
Earnings Yield	6.53%	-122.10%	29.27%	-51.82%	-17.34%	-14.85%
FCF Yield	-9.62%	-41.75%	-42.35%	-8.63%	-12.43%	-16.32%
Buyback Yield	-9.25%	-1.98%	-40.98%	-21.65%	-38.01%	-23.27%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Spero Therapeutics Financial Ratios

What is Spero Therapeutics's P/E ratio?

Spero Therapeutics's P/E ratio was 15.31 for fiscal 2025 (period ended Dec 31, 2025).

What is Spero Therapeutics's return on equity?

Spero Therapeutics's return on equity (ROE) was 16.3% for fiscal 2025 (period ended Dec 31, 2025). It was -89.6% a year earlier.

What is Spero Therapeutics's debt-to-equity ratio?

Spero Therapeutics's debt-to-equity ratio was 0.05 for fiscal 2025 (period ended Dec 31, 2025). It was 0.09 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition